The Ott Lab publishes novel research on SARS-CoV-2 variants Read More

Blog

Archives: Publications

Publications

Coronavirus protein interaction mapping in bat and human cells identifies molecular and genetic switches for immune evasion and replication

Batra J, Rutkowska M, Zhou Y, Ye C, Adavikolanu R, Young JM, Anand D, Verma S, Gordon M, Malpotra S, Cupic A, Kehrer T, Moen JM, Winters DM, Rojc A, Mena I, Aslam S, Martinez-Romero C, Conde Viñas I, Khalil Z, Farrugia K, Banerjee A, Tussia-Cohen D, Santos MD, Maji S, Muralidharan M, Foussard H, Chen IP, Fuchs R, Felipe CS, Zuliani-Alvarez L, Choudhury P, Obernier K, Gracias S, Suryawanshi R, Ibáñez C, Juste J, Pache L, Taha TY, Jouvenet N, Verba KA, Fraser JS, Demeret C, Stroud RM, van Bakel H, Ott M, Hagai T, Polacco B, Swaney DL, Echeverria I, Bouhaddou M, Eckhardt M, Malik HS, Martinez-Sobrido L, Miorin L, García-Sastre A, Krogan NJ.

bioRxiv [Preprint]. 2025 Jul 28:2025.07.26.666918. doi: 10.1101/2025.07.26.666918. PMID: 40766693; PMCID: PMC12324264.

Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus MPro inhibitors with potent in vivo efficacy

Detomasi TC, Degotte G, Huang S, Suryawanshi RK, Diallo A, Lizzadro L, Zapatero-Belinchón FJ, Taha TY, Li J, Richards AL, Hantz ER, Alam Z, Montano M, McCavitt-Malvido M, Gumpena R, Partridge JR, Correy GJ, Matsui Y, Charvat AF, Glenn IS, Rosecrans J, Revalde JL, Anderson D, Hultquist JF, Arkin MR, Neitz RJ, Swaney DL, Krogan NJ, Shoichet BK, Verba KA, Ott M, Renslo AR, Craik CS.

 

2025 Apr 25;11(17):eadt7836. doi: 10.1126/sciadv.adt7836. Epub 2025 Apr 23. PMID: 40267184; PMCID: PMC12017303.

Enhanced RNA replication and pathogenesis in recent SARS-CoV-2 variants harboring the L260F mutation in NSP6

Taha TY, Ezzatpour S, Hayashi JM, Ye C, Zapatero-Belinchón FJ, Rosecrans JA, Kimmerly GR, Chen IP, Walcott K, Kurianowicz A, Jorgens DM, Chaplin NR, Choi A, Buchholz DW, Sahler J, Hilt ZT, Imbiakha B, Vagi-Szmola C, Montano M, Stevenson E, Gordon M, Swaney DL, Krogan NJ, Whittaker GR, Martinez-Sobrido L, Aguilar HC, Ott M.

2025 Mar 31;21(3):e1013020. doi: 10.1371/journal.ppat.1013020. PMID: 40163530; PMCID: PMC11981139.

Structure-based discovery of a highly bioavailable, covalent SARS-CoV-2 major protease inhibitor with pan-coronavirus activity and potent in vivo efficacy.

Detomasi TC, Degotte , Huang S, Suryawanshi RK, Diallo A, Lizzardo L, Zapatero-Belinchon FJ, Taha TY, Li J, Richards A, Hantz ER, Alam Z, Montano M, McCavitt-Malvido M, Gumpena R, Partridge JR, Correy GJ, Charvat AF, Glenn IS, Rosecrans J, Revalde JL, Anderson D, Hultquist JF, Arkin MR, Neitz J, Swaney DL, Krogan NJ, Shoichet BK, Verba KA, Ott M, Renslo AR, Craik CS.

[Preprint] 2025, January 18. 2025.01.16.633443; doi: https://doi.org/10.1101/2025.01.16.633443

The Mac1 ADP-ribosylhydrolase is a Therapeutic Target for SARS-CoV-2.

Suryawanshi RK, Jaishankar P, Correy GJ, Rachman MM, O’Leary PC, Taha TY, Zapatero-Belinchón FJ, McCavittMalvido M, Doruk YU, Stevens MGV, Diolaiti ME, Jogalekar MP, Richards AL, Montano M, Rosecrans J, Matthay M, Togo T, Gonciarz RL, Gopalkrishnan S, Neitz RJ, Krogan NJ, Swaney DL, Shoichet BK, Ott M, Renslo AR, Ashworth A, Fraser JS.

2024 Aug 29:2024.08.08.606661. doi: 10.1101/2024.08.08.606661. PMID: 39149230; PMCID: PMC11326214.